Previous 10 | Next 10 |
- F irst demonstration of antiviral effect of nitric oxide -based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results demonstra...
Novan (NOVN) appoints John M. Gay as CFO. Mr. Gay joined Novan in May 2018 and has most recently served as Vice President, Finance and Corporate Controller, in addition to Principal Financial Officer and Corporate Secretary for the Company. Source: Press Release For further detail...
- John M. Gay , V ice P resident , Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer - James L. Bierman , seasoned industry executive with extensive stra...
FinancialBuzz.com News Commentary New York, NY (9/22/2020) – Due to increasing awareness amongst consumers on hygiene and preventive healthcare, the global surface disinfectant market is anticipated to grow significantly in the coming years. The current pandemic has caused major ...
LOS ANGELES, CA / ACCESSWIRE / September 22, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Virtual Panel, titled, " The Pursuit of Molluscum: Beetlejuice and Nobel Prizes" , hosted by John Vandermosten, Senior Biotech Analyst at Zack'...
The following slide deck was published by Novan, Inc. in conjunction with this Read more ...
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 - - In vitro assessments of ability of NITRICIL™ to inhibit the replication mechanisms of SARS-COV-2 (COVID-19) underway w...
- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14 th at 4:00 PM EDT - MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that Paula Brown Stafford, Chairman, Presiden...
Novan ( NOVN +2.5% ) announces that the first patient has been enrolled and dosed in its B-SIMPLE4 Phase 3 clinical study of SB206 , a topical antiviral gel, for the treatment of molluscum contagiosum, contagious skin infection. More news on: Novan, Inc., Healthcare stocks news...
- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - MORRISVILLE, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...